Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02892851
Other study ID # P111014
Secondary ID
Status Recruiting
Phase N/A
First received August 18, 2016
Last updated September 1, 2016
Start date March 2014
Est. completion date March 2018

Study information

Verified date August 2016
Source Assistance Publique - Hôpitaux de Paris
Contact Luc MALLET
Phone (0)1 49 81 30 52
Email luc.mallet@inserm.fr
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

Cocaine addiction is a chronic condition with severe cardiac, neurologic, psychiatric and social complications. Cocaine is the second most consumed illicit drug in France. Its prevalence has been multiplied by 3 between 2000 and 2008, and is still on the rise. Craving, the compulsive need to consume, is a key feature of cocaine addiction. It is also predictive of treatment efficacy. However, there is no validated treatment for severe cocaine dependence yet. Response to current psychological and medical treatment is poor, with 73% relapse after 3 months. Patients with severe cocaine addiction are thus in a therapeutic deadlock.

To address these unmet medical needs, the investigators designed a pilot study (n=2) to evaluate the safety and the efficacy of the deep brain stimulation of the subthalamic nuclei (STN-DBS) in severe cocaine addiction with at least one cardiac, neurologic or psychiatric complication. Indeed, compulsivity is a critical component of craving, and severe treatment-resistant obsessive compulsive disorder (OCD) are already successfully treated using STN-DBS. Moreover, animal studies recently demonstrated a therapeutic effect of STN-DBS in rats addicted to cocaine. Together, these two lines of research suggest a therapeutic effect of STN-DBS in cocaine addiction mediated by an anti-obsessive mechanism on craving.


Recruitment information / eligibility

Status Recruiting
Enrollment 2
Est. completion date March 2018
Est. primary completion date September 2017
Accepts healthy volunteers No
Gender Both
Age group 30 Years to 55 Years
Eligibility Inclusion Criteria:

- severe and resistant Cocaine Dependence for 5 years defined as:

- cocaine dependence (DSM IV),

- preferential use of cocaine in base form (crack or free-base) through smoke,

- non response to at least two well-conducted treatment with at least a stay in aftercare,

- severe physical complications (defined as a history of myocardial infarction, stroke).

- psychotic syndromes induced recurrent, severe lung disease "crack-lungs") occurred due to crack consumption and whose association with the crack use is known to the patient

- age between 30 and 55 years

- patient affiliated to a social security scheme

- patient signed an informed consent after receiving written information on the proposed procedure

Exclusion Criteria:

- a current opioid dependence will not be a criterion of non inclusion if the patient is undergoing substitution treatment (methadone or buprenorphine) and not injection of opiates for at least six months.

- patient trust

- pregnant, nursing or of childbearing potential without effective contraception

- current use of the intravenous route for the administration of the drugs is the risk of infection

- VIH infection or VHC unstabilized,

- cardiovascular and / or brain state is not compatible with the surgery,

- other disorder on Axis I not linked to cocaine use except:

- current or past dependence to nicotine,

- abuse or dependence on other psychoactive substances over a lifetime in remission for more than 6 months,

- current opioid dependence: if the patient is undergoing substitution treatment (methadone or buprenorphine) and not injection of opiates for at least 6 months,

- when other psychiatric disorders induced by substances.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
Deep brain stimulation of the subthalamic nuclei (STN-DBS)
3 phases : Parameter setting Cross-over double-bind (ON/OFF) Open Phase (ON)

Locations

Country Name City State
France Henri Mondor Hospital Creteil

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evolution of the Obsessive Compulsive Cocaine Scale (OCCS) craving score at month 6 No
Secondary Psychiatric assessment by standardized interview Month -2, Month 2, Month 3, Month 3+15 days, Month 4+15days, Month 6, Month 7, Month 8, Month 9, Month10 (+1,5) Yes
Secondary Cocaine Craving Questionnaire (CCQ) craving score Month -2, Month 2 (1day), Month 2 (2nd day), Month 2 (3rd day), Month 3, Month 3+15 days, Month 4+15days, Month 6, Month 7, Month 8, Month 9, Month 10 (+1,5) No
Secondary Self assessed addiction criteria Month -2, Month 2, Month 3, Month 3+15 days, Month 4+15days, Month 6, Month 7, Month 8, Month 9, Month10 (+1,5) No
Secondary Urine screening assay for cocaine use / Urine Drug Screening Month -2, Month 2, Month 3, Month 3+15 days, Month 4+15days, Month 6, Month 7, Month 8, Month 9, Month10 (+1,5) No
Secondary Capillary screening assay for cocaine use Month -2, Month 4,5 and Month 10 (+1,5) No
Secondary Evolution of Global Assessment of Functioning scale (GAF) Month -2, Month 2, Month 3, Month 3+15 days, Month 4+15days, Month 6, Month 7, Month 8, Month 9, Month10 (+1,5) No
See also
  Status Clinical Trial Phase
Completed NCT04336293 - sTMS for Substance Use-disordered Veterans N/A
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT01822587 - Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving Phase 2
Completed NCT01601743 - Exercise as a Behavioral Treatment for Cocaine Dependence N/A
Completed NCT02563769 - Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study Phase 1
Completed NCT01651377 - Pramipexole as a Treatment for Cocaine Dependence Phase 1
Completed NCT02768441 - Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots Early Phase 1
Completed NCT02626494 - Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Phase 4
Not yet recruiting NCT01319214 - Reducing Drug Craving Memories N/A
Recruiting NCT01259362 - Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients Phase 2
Completed NCT01211418 - Integrative Meditation (IM) for Cocaine Addiction N/A
Recruiting NCT03423667 - Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction Phase 2
Completed NCT01984177 - Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence N/A
Completed NCT01887366 - Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects Phase 2
Completed NCT01337297 - Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction Phase 1/Phase 2
Completed NCT01067846 - Cognitive Enhancement and Relapse Prevention in Cocaine Addiction N/A
Completed NCT01651364 - A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence Phase 1
Recruiting NCT03018236 - Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Phase 4
Completed NCT01929343 - Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving Phase 2
Completed NCT01281202 - Vigabatrin for the Treatment of Cocaine Dependency Phase 2/Phase 3